RedChip TV Interviews CEO of Duska Therapeutics, Inc.
* Reuters is not responsible for the content in this press release.
LA JOLLA, Calif., Feb. 25, 2008 (PRIME NEWSWIRE) -- Duska Therapeutics, Inc.
(OTCBB:DSKA), a biopharmaceutical company developing diagnostic and therapeutic
products based on adenosine 5'-triphosphate (ATP) and P2 receptor-related
technologies, announced today that the company's Chairman and Chief Executive
Officer, James S. Kuo, M.D., M.B.A., has been interviewed on RedChip TV, a
business-oriented television interview program. Dr. Kuo highlighted Duska's
scientific focus and targeted markets and detailed the company's progress and
strategies.
The interview was conducted on February 7, 2008, in conjunction with the
company's presentation at RedChip Companies' Small-Cap Investor Conference.
Duska Therapeutics' entire presentation to the analysts and brokers and
individual investors at the conference, and the CEO interview are available
online via following link: http://www.visualwebcaster.com/Redchipfeb2008/
About Duska Therapeutics, Inc.
Duska Therapeutics focuses on the development of therapeutic and diagnostic
products related to adenosine 5'-triphosphate (ATP), and cell-surface P2
receptors (P2R). Duska owns or has exclusive license rights to a number of
proprietary diagnostic and therapeutic applications, four of which are currently
in various stages of development in the fields of cardiac arrhythmias, male
infertility, chronic obstructive pulmonary disorders and cough, and glaucoma.
For more information, visit Duska's website at www.duskatherapeutics.com.
Forward-looking statements
This press release may contain forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended, that involve
risks and uncertainties that could cause actual events or results to differ
materially from the events or results described in the forward-looking
statements, The forward-looking statements are based on current expectations,
estimates and projections made by management. Duska intends for the
forward-looking statements to be covered by the safe harbor provisions for
forward-looking statements. Words such as "anticipates," "expects," "intends,"
"plans," "believes," "seeks," "estimates," or variations of such words are
intended to identify such forward-looking statements. All statements in this
release regarding the future outlook related to Duska are forward-looking
statements. Additional uncertainties and risks are described in Duska's most
recently filed SEC documents, such as its most recent annual report on Form
10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K
filed since the date of the last Form 10-KSB. Copies of these filings are
available through the SEC website at www.sec.gov. All forward-looking statements
are based upon information available to Duska on the date hereof. Duska
undertakes no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
-0-
CONTACT: Duska Therapeutics, Inc.
James S. Kuo, M.D., M.B.A., Chairman and CEO
858.551.5700
Fax: 858.551.5704
kuoj@duskatherapeutics.com
470 Nautilus Street, Suite 300
La Jolla, CA 92037
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters